Superworth

Nuvation Bio revenue NUVB

Sales by quarter and over the last twelve months, from 2023.

Last 12 months, to Jun 30, 2026
$169.9M
Latest quarter, Q2 FY26
$31.7M
+556% on a year earlier
Fiscal year 2025
$62.9M
+699% on the year before

Nuvation Bio's revenue was $169.9M over the twelve months to Jun 30, 2026, up 1084% on a year earlier.

In its latest quarter, Q2 FY26, it was $31.7M, up 556% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$62.9M+699%
FY2024$7.9Mn/a
FY2023n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$31.7M+556%$169.9M
Q1 FY26$83.2M+2599%$143M
Q4 FY25$41.9M+633%$62.9M
Q3 FY25$13.1M+1705%$26.7M
Q2 FY25$4.8M+237%$14.4M
Q1 FY25$3.1Mn/a$11M
Q4 FY24$5.7Mn/a$7.9M
Q3 FY24$727Kn/a$2.2M
Q2 FY24$1.4Mn/a$1.4M
Q1 FY24$0n/a$0
Q4 FY23$0n/an/a
Q3 FY23$0n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Nuvation Bio's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
NUVBNuvation Bio$169.9M
PAHCPhibro Animal Health$1.5B+17% a year
ANIPANI Pharmaceuticals$978.4M+31% a year
ANABAnaptysbion/m
PCRXPacira BioSciences$746.2M+6% a year
HRMYHarmony Biosciences$959.9M+24% a year
OMEROmerosn/m
PBHPrestige Consumer Healthcare$1.1B−1% a year
AMPHAmphastar Pharmaceuticals$730M+1% a year
NRIXNurix Therapeutics$701.9M
ABUSArbutus Biopharma$181.7M
Peer median$853M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Nuvation Bio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.